Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Lumen Bioscience

Ownership
Private
Employees
~90
Therapeutic Areas
GastroenterologyMetabolic DisordersInfectious Diseases
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Biologic drugstherapeutic proteinsantibodiescytokinesenzyme cocktails

Lumen Bioscience General Information

Lead program LMN-801 for weight loss is in development, with several earlier-stage metabolic programs. LMN-201 for C. difficile infection prevention was the first rationally engineered, complex biologic cocktail to enter human clinical trials.

Contact Information

Website
https://lumen.bio/
Primary Industry
Biotech
Corporate Office
Seattle, Washington
USA

Drug Pipeline

LMN-801
Preclinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Lumen Bioscience's pipeline data

Book a demo

Key Partnerships

BARDA, CARBX, The Bill & Melinda Gates Foundation, USAMRD/MTEC

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Lumen Bioscience Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Lumen Bioscience's complete valuation and funding history, request access »

Lumen Bioscience Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals